Top

Published in:

01-03-2022 | Targeted Therapy | Case Report- Pituitaries

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor

Authors: Flavie Grenier-Chartrand, Sami Barrit, Marie Lucie Racu, Sylvie Luce, Julien Spitaels, Niloufar Sadeghi-Meibodi, Laetitia Lebrun, Isabelle Salmon, Florence Lefranc, Olivier De Witte

Published in: Acta Neurochirurgica | Issue 3/2022

Abstract

Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.

Das L, Vaiphei K, Rai A et al (2021) Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. Endocr Connect 10(4):387–400. https://doi.org/10.1530/EC-20-0621CrossRefPubMedPubMedCentral

Dawoud FM, Naylor RM, Giannini C, Swanson AA, Meyer FB, Uhm JH (2020) TTF-1 positive posterior pituitary tumor: limitations of current treatment and potential new hope in BRAF V600E mutation variants. Clin Neurol Neurosurg 196:106059. https://doi.org/10.1016/j.clineuro.2020.106059CrossRefPubMed

Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019) Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers 11(12):1950. https://doi.org/10.3390/cancers11121950CrossRefPubMedCentral

Hasegawa H, Van Gompel JJ, Oushy SH et al (2021) A comprehensive study of spindle cell oncocytoma of the pituitary gland: series of 6 cases and meta-analysis of 85 cases. World Neurosurg 149:e197–e216. https://doi.org/10.1016/j.wneu.2021.02.051CrossRefPubMed

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8CrossRefPubMed

Maraka S, Janku F (2018) BRAF alterations in primary brain tumors. Discov Med 26(141):51–60PubMed

Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243. https://doi.org/10.1097/PAS.0b013e31829723e7CrossRef

Mete O, Lopes MB, Asa SL (2013) Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 37(11):1694–1699. https://doi.org/10.1007/s12022-017-9498-zCrossRefPubMed

Miller MB, Bi WL, Ramkissoon LA, et al (2016) MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget 7(24):37054–37063. https://doi.org/10.18632/oncotarget.9244

10.

Peuvrel L, Dréno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444. https://doi.org/10.1007/s40257-014-0088-2CrossRefPubMed

11.

Roncaroli F, Chatterjee D, Giannini C et al (2020) Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF-1-positive sellar lesions. Neuropathol Appl Neurobiol 46(5):493–505. https://doi.org/10.1111/nan.12622CrossRefPubMed

12.

Salge-Arrieta FJ, Carrasco-Moro R, Rodríguez-Berrocal V, Pian H, Martínez-San Millán JS, Iglesias P, Ley-Urzáiz L (2019) Clinical features, diagnosis and therapy of pituicytoma: an update. J Endocrinol Invest 42(4):371–384. https://doi.org/10.1007/s40618-018-0923-zCrossRefPubMed

13.

Sollfrank L, Lettmaier S, Erdmann M, Uslu U (2019) Panniculitis under successful targeted inhibition of the MAPK/ERK signaling pathway in a patient with BRAF V600E-mutated spindle cell oncocytoma of the pituitary gland. Anticancer Res 39(7):3955–3959. https://doi.org/10.21873/anticanres.13549

14.

Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, Nasrallah MP (2019) Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol Commun 7(1):69. https://doi.org/10.1186/s40478-019-0722-6CrossRefPubMedPubMedCentral

Title: Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor
Authors: Flavie Grenier-Chartrand
Sami Barrit
Marie Lucie Racu
Sylvie Luce
Julien Spitaels
Niloufar Sadeghi-Meibodi
Laetitia Lebrun
Isabelle Salmon
Florence Lefranc
Olivier De Witte
Publication date: 01-03-2022
Publisher: Springer Vienna
Keyword: Targeted Therapy
Published in: Acta Neurochirurgica / Issue 3/2022
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-022-05109-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

How I do it: two-step transposition technique during endoscopic microvascular decompression for trigeminal neuralgia

Combined use of vancomycin powder and betadine irrigation lowers the incidence of postcraniotomy wound infection in low-risk cases: a single-center risk-stratified cohort analysis

Cerebral venous sinus thrombosis in infant with COVID-19

Response to letter: “Stereotactic biopsies of brainstem lesions: dilemma on the best trajectory”

The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study

Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine–based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage